Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies

← catalyst calendar

NCT05209295

Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.

Phase
Phase 1
Status
Terminated
Study type
Interventional
Design
Non randomized · None · Basic science
Enrollment
2actual
Sites
18
Countries
Argentina, Colombia, Germany +2

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Why the sponsor stopped it

Insufficient Enrollment

As filed on the registry record, in the sponsor's own words.

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2024-07-12actualWhen the study began enrolling
Primary completion2025-04-20actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2025-04-20actualThe whole study's end, after follow-up
First posted2022-01-26actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-01-12actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

  • Hepatic Insufficiency
  • Neoplasms

Intervention

  • Drug: Onureg — also filed as CC-486, Oral Azacitidine

Primary outcomes

what the primary-completion date above is the date OF
AUC0-t: Estimation of area under the plasma concentration-time curve (AUC) calculated from time zero to the last measured time point
measured Day 1
AUC0-∞: Estimation of AUC calculated from time zero to infinity
measured Day 1
Cmax: Observed maximum concentration
measured Day 1

Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed